History
|
2011
|
Innovacell successfully completes the multi-centre Phase IIb clinical trial in 32 centres in four European countries and starts a multi-centre Phase III clinical trial in eleven European countries. | |
|
2010 |
Innovacell initiates clinical trial Phase IIb program for ICES13 in four European countries. | |
| 2009 |
Innovacell receives approval by European authorities for its clinical trial program for ICES13. Innovacell establishes cryopreservation methods in order to store, handle, and ship therapeutic cell cultures to the highest safety standards. |
|
| 2008 | Innovacell becomes a joint-stock company (AG), which remains privately held. First patients receive treatment with ICEF15 in clinical trials. |
|
| 2007 | The European Patent Office (EPO) grants patent protection to Innovacell for its innovative application device. More than 500 patients are treated using Innovacell's cell-based therapy. |
|
| 2006 | First therapies are marketed. | |
| 2005 | Innovacell commissions Europe’s largest production facility for the routine production of autologous cell therapies. | |
| 2002 | First patients receive treatment in clinical trials. | |
| 2001 | Innovacell wins Tyrolean business plan competition "adventure X". | |
| 2000 | Innovacell Biotechnologie GmbH is founded in Innsbruck as a spin-off company of the University Hospital Innsbruck, Austria. |